Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia
Phase of Trial: Phase IV
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Allotransplant rejection; Ataxia; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; Immune thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
- Focus Adverse reactions
- Sponsors Baxalta; Shire
- 06 Nov 2017 Planned End Date changed from 1 Jan 2020 to 31 Jan 2020.
- 06 Nov 2017 Planned primary completion date changed from 1 Jan 2020 to 31 Jan 2020.
- 24 Sep 2015 New trial record